Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for idiopathic pulmonary fibrosis
2025-523341-10-00Phase 2Authorised
- Sponsor
- Philipps-Universität Marburg
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Metformin with Placebo (2 arms). Primary endpoint: Change from baseline in serum PRO-C3. Planned start Sep 2026; status: authorised.
02
Drugs
metformin
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2025-523341-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523341-10-00.